Radionetics Oncology
Brett Ewald is the Chief Operating Officer at Radionetics Oncology. Prior to this role, Brett served as the Senior Vice President of Development and Corporate Strategy at DNAtrix and the Head of Clinical Operations Planning at Novartis Oncology. With a background in pharmacology and biology, Brett has extensive experience in the oncology field, focusing on early clinical development and strategy. Through his various roles, Brett has demonstrated strong leadership, strategic planning, and successful development of clinical trials and partnerships within the pharmaceutical industry.
Radionetics Oncology
Radionetics Oncology is a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications. The company’s platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes to a broad range of cancers by binding selectively to peptide receptors that are selectively expressed on these tumors. This nonpeptide technology addresses many of the significant challenges currently facing peptide and protein targeted radiotherapeutics, particularly in the realm of optimizing drug-like characteristics and manufacturing. The company is rapidly advancing a pipeline of drug candidates to treat a broad range of cancers and is conducting additional drug discovery efforts to identify drug candidates for additional receptor targets in collaboration with Crinetics Pharmaceuticals.